


## AG2034

Cat. No.:	HY-10819
CAS No.:	177575-17-6
Molecular Formula:	C <sub>18</sub> H <sub>21</sub> N <sub>5</sub> O <sub>6</sub> S <sub>2</sub>
Molecular Weight:	467.52
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	AG2034 is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a K <sub>i</sub> of 28 nM against human GARFT, and it binds with high affinity to the folate receptor (K <sub>d</sub> of 0.0042 nM). Additionally, AG2034 is a substrate for rat liver folylpolyglutamate synthetase, with a K <sub>m</sub> of 6.4 μM. AG2034 inhibits the growth of L1210 and CCRF-CEM cells, with IC <sub>50</sub> values of 4 nM and 2.9 nM, respectively, and it has demonstrated antitumor activity in xenograft models such as 6C3HED <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 28 nM (GARFT) <sup>[1]</sup>

### REFERENCES

- [1]. Boritzki T.J, et al. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs. 1996;14(3):295-303.
- [2]. Roberts JD, et al. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7.
- [3]. Hartman PA, et al. Gradient reversed-phase high-performance liquid chromatographic separation of paldimycin (U-70,138) antibiotics and related compounds. J Chromatogr. 1987 Jan 9;385:363-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA